Researchers sought to determine 1-year outcomes in patients being treated with tirzepatide who have atrial fibrillation.

Boston Scientific, Medtronic, Abbott and J&J unveiled new data for their PFA devices in tandem with the Heart Rhythm ...

Abbott has reported new data from its prospective, non-randomised Volt CE Mark Study, indicating that individuals treated ...

The benefit of GLP-1 therapy couldn’t be explained by weight loss, suggesting that some pleiotropic effects may be at work.

Emerging pulsed field ablation systems had their moments in the spotlight at the annual meeting of the Heart Rhythm Society ...

SGLT2 inhibitors, compared with GLP1 agonists, significantly lower risk for atrial fibrillation in patients with type 2 diabetes.

For patients newly diagnosed with atrial fibrillation during hospitalization for other causes, most are not dispensed anticoagulants in the year after discharge.

Patients with a high probability of HFpEF may experience greater benefits from atrial fibrillation ablation than those with a ...

GLP-1 use significantly lowered risk for atrial fibrillation-related events for patients with diabetes, AF and obesity, with ...

Pulsed field ablation (PFA) technology made some advances with 12-month results for the Globe Pulsed Field System in ...

For patients newly diagnosed with atrial fibrillation (AF) during hospitalization for other causes, most are not dispensed ...